[Systemic cyclosporin A therapy in high risk keratoplasty].
The authors have treated seven patients (eight eyes) with systemic cyclosporin-A for up to 1.5 years after high-risk keratoplasty à chaud. The fellow eye was compromised in all except one of the patients treated. Two patients (three eyes) had had a corneal perforation as a result of alkali burns or herpetic keratouveitis without previous grafting; five patients (five eyes) had had multiple corneal grafts (up to three grafts in one eye). Each patient received the medication pre- and postoperatively in organ transplant concentrations. In each case reported, the graft survived; however, visual acuity was reduced due to epithelial problems in four of eight eyes. Cyclosporin A may help to provide a better prognosis for allogeneic keratoplasty in high-risk situations. Long-term results in larger populations and comparison with other modes of minimizing graft rejection will define the role of cyclosporin A in allogeneic high-risk keratoplasty.
Bialasiewicz
A A
AA
Naumann
G O
GO
D000328:Adult; D000368:Aged; D003316:Corneal Diseases / Q000601:surgery*; D016039:Corneal Transplantation / Q000276:immunology; D003524:Cyclosporins / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D012307:Risk Factors
D003524:Cyclosporins
Systemische Zyklosporin-A-Therapie bei Risiko-Keratoplastik.